CG
NXTC icon

Cutler Group’s NextCure NXTC Stock Holding History

Cutler Group’s Portfolio NXTC Stock Details NXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-58
Closed -$1K – 4167
2023
Q2 		$1K Hold
58
– – ﹤0.01% 3355
2023
Q1 		$1K Hold
58
– – ﹤0.01% 3499
2022
Q4 		$0 Sell
58
-9
-13% -$207 ﹤0.01% 4955
2022
Q3 		$2K Hold
67
– – ﹤0.01% 4259
2022
Q2 		$3K Hold
67
– – ﹤0.01% 4081
2022
Q1 		$3K Hold
67
– – ﹤0.01% 4497
2021
Q4 		$4K Hold
67
– – ﹤0.01% 4366
2021
Q3 		$5K Hold
67
– – ﹤0.01% 4477
2021
Q2 		$6K Hold
67
– – ﹤0.01% 4322
2021
Q1 		$8K Buy
+67
New +$9.7K ﹤0.01% 4005
2020
Q4 		– Sell
-42
Closed -$5.43K – 5298
2020
Q3 		$4K Sell
42
-50
-54% -$6.15K ﹤0.01% 3678
2020
Q2 		$23K Buy
92
+84
+1,050% +$32K ﹤0.01% 2274
2020
Q1 		$3K Sell
8
-109
-93% -$58.2K ﹤0.01% 3333
2019
Q4 		$78K Buy
+117
New +$58.7K ﹤0.01% 1343

Other funds holding NXTC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Cutler Group's NXTC Position: Q3 2023 in Review

Cutler Group sold out of NextCure (NXTC) in Q3 2023, closing a stake of 58 shares — an estimated $1K sold.

Cutler Group first reported a position in NXTC in Q4 2019 and held it in 14 quarters. The position peaked at $78K in Q4 2019. 39 funds tracked by Wall St. Rank hold NXTC as of Q3 2023.

  • Cutler Group reported no remaining NextCure position as of Q3 2023 after selling out during the quarter.
  • Cutler Group sold 58 NextCure shares in Q3 2023, an estimated $1K.
  • Cutler Group first reported a position in NextCure in Q4 2019 and held it in 14 quarters.
  • Cutler Group's NextCure position peaked at $78K in Q4 2019.
  • 39 funds tracked by Wall St. Rank held NextCure as of Q3 2023.

Based on Cutler Group's 13F filing for Q3 2023, filed 7 Nov 2023.